FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / PLoS One / The sodium-glucose co-transporter 2 inhibitor velagliflozin ...
PloS one2018; 13(9); e0203655; doi: 10.1371/journal.pone.0203655

The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies.

Abstract: There are no registered veterinary drugs for treating insulin dysregulation and preventing insulin-associated laminitis in horses. Velagliflozin is a sodium-glucose co-transport 2 inhibitor that reduces renal glucose reabsorption, promotes glucosuria, and consequently, decreases blood glucose and insulin concentrations. This study aimed to determine if velagliflozin reduced hyperinsulinemia and prevented laminitis in insulin-dysregulated ponies fed a challenge diet high in non-structural carbohydrates (NSC). An oral glucose test (1 g dextrose/kg BW) was used to screen 75 ponies for insulin dysregulation, of which 49 ponies with the highest insulin concentrations were selected. These animals were assigned randomly to either a treated group (n = 12) that received velagliflozin (0.3 mg/kg BW, p.o., s.i.d.) throughout the study, or a control group (n = 37). All ponies were fed a maintenance diet of alfalfa hay for 3 weeks, before transferring to a challenge diet (12 g NSC/kg BW/d) for up to 18 d. Blood glucose and serum insulin concentrations were measured over 4 h after feeding, on d 2 of the diet. The maximum glucose concentration was 22% lower (P = 0.014) in treated animals, with a geometric mean (95% CI) of 9.4 (8.0-11.0) mM, versus 12.1 (10.7-13.7) mM in the controls. This was reflected by lower (45%) maximum insulin concentrations in the treated group (P = 0.017), of 149 (97-228) μIU/mL, versus 272 (207-356) μIU/mL for controls. The diet induced Obel grade 1 or 2 laminitis in 14 of the 37 controls (38%), whereas no velagliflozin-treated pony developed laminitis (P = 0.011). Velagliflozin was well-tolerated, with no hypoglycemia or any clinical signs of adverse effects. The main limitation of this study was the sample size. Velagliflozin shows promise as a safe and effective compound for treating insulin dysregulation and preventing laminitis by reducing the hyperinsulinemic response to dietary NSC.
Get Full Text
Publication Date: 2018-09-13 PubMed ID: 30212530PubMed Central: PMC6136744DOI: 10.1371/journal.pone.0203655Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Clinical Trial
  • Veterinary
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research tests the effectiveness of the drug Velagliflozin in treating insulin dysregulation and preventing laminitis in ponies.

Objectives of the Study

  • The main aim of the research was to study the impact of Velagliflozin, a sodium-glucose co-transport 2 inhibitor, on insulin-dysregulated ponies.
  • The researchers aimed to see if this drug could reduce hyperinsulinemia (excess levels of insulin in the blood) and prevent laminitis (a severe and painful inflammatory condition affecting the horse’s hoof).

Methodology

  • An oral glucose test was conducted on 75 ponies to identify those with insulin dysregulation. Out of these, 49 ponies with the highest insulin concentrations were selected.
  • Among the selected group, 12 ponies were randomly chosen and treated with Velagliflozin, while the remaining 37 acted as control, receiving no treatment.
  • All ponies were initially fed an alfalfa hay diet for three weeks before switching to a high non-structural carbohydrate (NSC) diet for up to 18 days.
  • Blood glucose and serum insulin concentrations were measured after feeding, on the second day of the new diet.

Results of the Study

  • The maximum glucose concentration in the treated ponies was 22% lower compared to the control group.
  • The maximum insulin concentrations were also reduced by 45% in the treated group compared to controls.
  • In the control group, 14 out of 37 ponies developed Obel grade 1 or 2 laminitis, but none of the Velagliflozin-treated ponies developed this condition.

Conclusions and Limitations

  • Velagliflozin was found to be well-tolerated by the ponies, with no signs of hypoglycemia or any adverse effects.
  • This drug has potential as a safe and effective compound for treating insulin dysregulation and preventing laminitis in ponies.
  • The study conceded that a key limitation was the small sample size. More studies with a larger pool of subjects could offer more definitive conclusions.

Cite This Article

APA
Meier A, Reiche D, de Laat M, Pollitt C, Walsh D, Sillence M. (2018). The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One, 13(9), e0203655. https://doi.org/10.1371/journal.pone.0203655

Publication

PloS one
ISSN: 1932-6203
NlmUniqueID: 101285081
Country: United States
Language: English
Volume: 13
Issue: 9
Pages: e0203655
PII: e0203655

Researcher Affiliations

Meier, Alexandra
  • Earth, Environmental and Biological Sciences School, Queensland University of Technology, Brisbane, Queensland, Australia.
Reiche, Dania
  • Boehringer Ingelheim Vetmedica, Ingelheim am Rhein, Germany.
de Laat, Melody
  • Earth, Environmental and Biological Sciences School, Queensland University of Technology, Brisbane, Queensland, Australia.
Pollitt, Christopher
  • Australian Equine Laminitis Research Unit, School of Veterinary Science, University of Queensland, St Lucia, Queensland, Australia.
Walsh, Donald
  • Animal Health Foundation, Pacific, Missouri, United States of America.
Sillence, Martin
  • Earth, Environmental and Biological Sciences School, Queensland University of Technology, Brisbane, Queensland, Australia.

MeSH Terms

  • Adrenocorticotropic Hormone / analysis
  • Animals
  • Blood Glucose / analysis
  • Body Weight / drug effects
  • Diet
  • Foot Diseases / pathology
  • Foot Diseases / prevention & control
  • Foot Diseases / veterinary
  • Glucose Tolerance Test
  • Hoof and Claw / pathology
  • Horse Diseases / drug therapy
  • Horse Diseases / pathology
  • Horses
  • Hyperinsulinism / drug therapy
  • Hyperinsulinism / pathology
  • Insulin / blood
  • Nitriles / pharmacology
  • Nitriles / therapeutic use
  • Random Allocation
  • Sodium-Glucose Transport Proteins / antagonists & inhibitors
  • Sodium-Glucose Transport Proteins / metabolism

Conflict of Interest Statement

The funders of this study have filed international patent applications on the use of SGLT2 inhibitors in horses: Boehringer Ingelheim Vetmedica GmbH, WO2014/161836 and WO2015/150299 entitled “Treatment of metabolic disorders in equine animals”. Boehringer Ingelheim is currently exploring the possibility of the commercial use of velagliflozin in horses. DR is an employee of Boehringer Ingelheim and is named as an inventor on the above patent. This does not alter our adherence to all PLOS ONE policies on sharing data and materials. All other authors have declared that no competing interests exist.

References

This article includes 38 references
  1. Karikoski NP, Horn I, McGowan TW, McGowan CM. The prevalence of endocrinopathic laminitis among horses presented for laminitis at a first-opinion/referral equine hospital.. Domest Anim Endocrinol 2011 Oct;41(3):111-7.
    doi: 10.1016/j.domaniend.2011.05.004pubmed: 21696910google scholar: lookup
  2. de Laat MA, McGree JM, Sillence MN. Equine hyperinsulinemia: investigation of the enteroinsular axis during insulin dysregulation.. Am J Physiol Endocrinol Metab 2016 Jan 1;310(1):E61-72.
    doi: 10.1152/ajpendo.00362.2015pubmed: 26530154google scholar: lookup
  3. McGowan CM, Frost R, Pfeiffer DU, Neiger R. Serum insulin concentrations in horses with equine Cushing's syndrome: response to a cortisol inhibitor and prognostic value.. Equine Vet J 2004 Apr;36(3):295-8.
    pubmed: 15147141doi: 10.2746/0425164044877288google scholar: lookup
  4. Asplin KE, Sillence MN, Pollitt CC, McGowan CM. Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies.. Vet J 2007 Nov;174(3):530-5.
    doi: 10.1016/j.tvjl.2007.07.003pubmed: 17719811google scholar: lookup
  5. Donaldson MT, LaMonte BH, Morresey P, Smith G, Beech J. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).. J Vet Intern Med 2002 Nov-Dec;16(6):742-6.
    pubmed: 12465775doi: 10.1892/0891-6640(2002)016<0742:twpoco>2.3.co;2google scholar: lookup
  6. Frank N, Tadros EM. Insulin dysregulation.. Equine Vet J 2014 Jan;46(1):103-12.
    doi: 10.1111/evj.12169pubmed: 24033478google scholar: lookup
  7. Freestone JF, Beadle R, Shoemaker K, Bessin RT, Wolfsheimer KJ, Church C. Improved insulin sensitivity in hyperinsulinaemic ponies through physical conditioning and controlled feed intake.. Equine Vet J 1992 May;24(3):187-90.
    pubmed: 1606931doi: 10.1111/j.2042-3306.1992.tb02812.xgoogle scholar: lookup
  8. Powell DM, Reedy SE, Sessions DR, Fitzgerald BP. Effect of short-term exercise training on insulin sensitivity in obese and lean mares.. Equine Vet J Suppl 2002 Sep;(34):81-4.
    pubmed: 12405664doi: 10.1111/j.2042-3306.2002.tb05396.xgoogle scholar: lookup
  9. Menzies-Gow NJ. Endocrinopathic laminitis: reducing the risk through diet and exercise.. Vet Clin North Am Equine Pract 2010 Aug;26(2):371-8.
    doi: 10.1016/j.cveq.2010.04.005pubmed: 20699181google scholar: lookup
  10. White J. Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT2 inhibition.. Clinical Diabetes 2010;28:5–10.
  11. Poirée JC, Vannier C, Sudaka P, Fehlmann M. Glucose transport by horse kidney brush borders. I.--Transport properties of brush border membrane closed vesicles.. Biochimie 1978 Sep 29;60(6-7):645-51.
    pubmed: 719044doi: 10.1016/s0300-9084(78)80783-4google scholar: lookup
  12. Meier AD, de Laat MA, Reiche DB, Pollitt CC, Walsh DM, McGree JM, Sillence MN. The oral glucose test predicts laminitis risk in ponies fed a diet high in nonstructural carbohydrates.. Domest Anim Endocrinol 2018 Apr;63:1-9.
    doi: 10.1016/j.domaniend.2017.10.008pubmed: 29172109google scholar: lookup
  13. Frank N, Bailey S, Durham A, Kritchevsky J, Menzies-Gow N, Tadros L. Recommendations for the diagnosis and treatment of equine metabolic syndrome (EMS) Equine Endocrinology Group.. Junen2016.
  14. Henneke DR, Potter GD, Kreider JL, Yeates BF. Relationship between condition score, physical measurements and body fat percentage in mares.. Equine Vet J 1983 Oct;15(4):371-2.
    pubmed: 6641685doi: 10.1111/j.2042-3306.1983.tb01826.xgoogle scholar: lookup
  15. Carter RA, Geor RJ, Burton Staniar W, Cubitt TA, Harris PA. Apparent adiposity assessed by standardised scoring systems and morphometric measurements in horses and ponies.. Vet J 2009 Feb;179(2):204-10.
    doi: 10.1016/j.tvjl.2008.02.029pubmed: 18440844google scholar: lookup
  16. Mc Gowan TW, Pinchbeck GP, Mc Gowan CM. Evaluation of basal plasma α-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses.. Equine Vet J 2013 Jan;45(1):66-73.
    doi: 10.1111/j.2042-3306.2012.00575.xpubmed: 22563728google scholar: lookup
  17. Bertin FR, de Laat MA. The diagnosis of equine insulin dysregulation.. Equine Vet J 2017 Sep;49(5):570-576.
    doi: 10.1111/evj.12703pubmed: 28543410google scholar: lookup
  18. Neumiller JJ. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.. Drugs Context 2014;3:212262.
    pmc: PMC4079288pubmed: 24991224doi: 10.7573/dic.212262google scholar: lookup
  19. List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.. Kidney Int Suppl 2011 Mar;(120):S20-7.
    pubmed: 21358698doi: 10.1038/ki.2010.512google scholar: lookup
  20. Karikoski NP, Patterson-Kane JC, Singer ER, McFarlane D, McGowan CM. Lamellar pathology in horses with pituitary pars intermedia dysfunction.. Equine Vet J 2016 Jul;48(4):472-8.
    doi: 10.1111/evj.12450pubmed: 25869529google scholar: lookup
  21. McGowan CM, Frost R, Pfeiffer DU, Neiger R. Serum insulin concentrations in horses with equine Cushing's syndrome: response to a cortisol inhibitor and prognostic value.. Equine Vet J 2004 Apr;36(3):295-8.
    pubmed: 15147141doi: 10.2746/0425164044877288google scholar: lookup
  22. McGowan TW, Pinchbeck GP, McGowan CM. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses.. Equine Vet J 2013 Jan;45(1):74-9.
    doi: 10.1111/j.2042-3306.2012.00578.xpubmed: 22594955google scholar: lookup
  23. McFarlane D, Johnson P, Schott H. Pituitary pars intermedia dysfunction. In: Belknap J, Geor R, editors. Equine Laminitis. Wiley Blackwell; 2017. pp. 334–340.
  24. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.. J Pharmacol Exp Ther 2008 Oct;327(1):268-76.
    doi: 10.1124/jpet.108.140210pubmed: 18583547google scholar: lookup
  25. Treiber KH, Kronfeld DS, Hess TM, Byrd BM, Splan RK, Staniar WB. Evaluation of genetic and metabolic predispositions and nutritional risk factors for pasture-associated laminitis in ponies.. J Am Vet Med Assoc 2006 May 15;228(10):1538-45.
    doi: 10.2460/javma.228.10.1538pubmed: 16677122google scholar: lookup
  26. Pleasant RS, Suagee JK, Thatcher CD, Elvinger F, Geor RJ. Adiposity, plasma insulin, leptin, lipids, and oxidative stress in mature light breed horses.. J Vet Intern Med 2013 May-Jun;27(3):576-82.
    doi: 10.1111/jvim.12056pubmed: 23517373google scholar: lookup
  27. Morgan RA, McGowan TW, McGowan CM. Prevalence and risk factors for hyperinsulinaemia in ponies in Queensland, Australia.. Aust Vet J 2014 Apr;92(4):101-6.
    doi: 10.1111/avj.12159pubmed: 24673135google scholar: lookup
  28. Vick MM, Adams AA, Murphy BA, Sessions DR, Horohov DW, Cook RF, Shelton BJ, Fitzgerald BP. Relationships among inflammatory cytokines, obesity, and insulin sensitivity in the horse.. J Anim Sci 2007 May;85(5):1144-55.
    doi: 10.2527/jas.2006-673pubmed: 17264235google scholar: lookup
  29. Carter RA, Treiber KH, Geor RJ, Douglass L, Harris PA. Prediction of incipient pasture-associated laminitis from hyperinsulinaemia, hyperleptinaemia and generalised and localised obesity in a cohort of ponies.. Equine Vet J 2009 Feb;41(2):171-8.
    pubmed: 19418747doi: 10.2746/042516408x342975google scholar: lookup
  30. Suagee JK, Corl BA, Crisman MV, Pleasant RS, Thatcher CD, Geor RJ. Relationships between body condition score and plasma inflammatory cytokines, insulin, and lipids in a mixed population of light-breed horses.. J Vet Intern Med 2013 Jan-Feb;27(1):157-63.
    doi: 10.1111/jvim.12021pubmed: 23216530google scholar: lookup
  31. Fielder S. Serum Biochemical Reference Ranges–Appendixes- Veterinary Manual [internet]. 2018.
  32. Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors.. Metabolism 2014 Oct;63(10):1228-37.
    doi: 10.1016/j.metabol.2014.06.018pubmed: 25104103google scholar: lookup
  33. Hoenig M, Clark M, Schaeffer DJ, Reiche D. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats.. J Vet Pharmacol Ther 2018 Apr;41(2):266-273.
    pubmed: 29139146doi: 10.1111/jvp.12467google scholar: lookup
  34. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.. Clin J Am Soc Nephrol 2010 Jan;5(1):133-41.
    doi: 10.2215/CJN.04010609pubmed: 19965550google scholar: lookup
  35. Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, Rutten GE. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus.. Clin Infect Dis 2005 Aug 1;41(3):281-8.
    doi: 10.1086/431587pubmed: 16007521google scholar: lookup
  36. Chen LH, Leung PS. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.. Diabetes Obes Metab 2013 May;15(5):392-402.
    doi: 10.1111/dom.12064pubmed: 23331516google scholar: lookup
  37. Geor RJ. Pasture-associated laminitis.. Vet Clin North Am Equine Pract 2009 Apr;25(1):39-50, v-vi.
    doi: 10.1016/j.cveq.2009.01.004pubmed: 19303549google scholar: lookup
  38. Karikoski NP, McGowan CM, Singer ER, Asplin KE, Tulamo RM, Patterson-Kane JC. Pathology of Natural Cases of Equine Endocrinopathic Laminitis Associated With Hyperinsulinemia.. Vet Pathol 2015 Sep;52(5):945-56.
    doi: 10.1177/0300985814549212pubmed: 25232034google scholar: lookup

Citations

This article has been cited 15 times.
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.